Posted: March 15, 2013
By: Morrison & Foerster

The all-encompassing scope of personalized medicine is expected to drive new levels of partnership activity across the life sciences spectrum. To better understand the role of collaboration in this area, L.E.K. Consulting assessed broader decision-support trends and tracked the emergence of more holistic solutions beyond companion diagnostic tests. L.E.K.'s findings confirm that more holistic decision support tests and solutions are coming and will require stakeholders to think differently about how they establish themselves, using a broad network of partners and strategic initiatives.

Posted: February 19, 2013
By: L.E.K. Consulting

The all-encompassing scope of personalized medicine is expected to drive new levels of partnership activity across the life sciences spectrum. To better understand the role of collaboration in this area, L.E.K. Consulting assessed broader decision-support trends and tracked the emergence of more holistic solutions beyond companion diagnostic tests. L.E.K.'s findings confirm that more holistic decision support tests and solutions are coming and will require stakeholders to think differently about how they establish themselves, using a broad network of partners and strategic initiatives.

Posted: March 4, 2013
By: Dando, Weiss & Colucci

Aimed at entities who are involved in the planning and implementation of pre-competitive or early stage collaborations within large scale networks which aim towards providing a long term profitable outcome, this paper will provide insight on understanding the dynamic, the benefits and the pitfalls of such a plan and how to extract the most value from such a project. DWC illustrates their experiences in optimizing management structures specifically for the degenerative diseases/regenerative medicine sector, which can create enhanced value addition for all, and can be adapted for use in other sectors.

Posted: February 1, 2013
By: Clinipace Worldwide

Approximately 20% of the world's clinical trials are conducted in Europe, which is defined in this context as the 30 countries that contribute to the European Medicines Agency (EMA). Compared with single countries, such as the US or Japan, the confederation of separate nations that comprise Europe can present both challenges and opportunities for clinical trials at any stage of drug development.

Posted: January 2, 2013
By: Avalere Health LLC

This paper explores the role of robust "clinical value messaging" in enhancing evidence-based care and encouraging appropriate practice changes in a way that is beneficial to providers, payers, manufacturers, and patients. Specifically, we evaluate how strong clinical value messages can potentially shorten the time it takes for external stakeholders to assess new product data, and may ultimately affect the coverage policies for and use of a new product. While this evaluation is U.S.-based and highlights issues specific to our healthcare system, the concept of clinical value messaging is almost certainly relevant to those countries experiencing similar challenges.

Posted: January 2, 2013
By: China Bio LLC

This white paper provides a four year analysis of strategic partnership activity in China's pharmaceutical industry from 2008-2011.

Posted: January 2, 2013
By: ARX (Algorithmic Research)

This eBook explores 10 ways you can use digital signatures to make your operations and FDA compliance easier and more efficient. It also offers the 10 most important things to seek in a digital signature solution that must meet the strictest technical standards, industry regulations and business requirements.

Posted: January 2, 2013
By: China Bio LLC

This presentation gives a comprehensive overview on the state of biotech in China with a focus on investment and partnering activities.

Posted: January 2, 2013
By: Morrison & Foerster

BioMeter takes the pulse of the industry by looking at a key measure of deal value—upfront payments—for deals in all stages of development. In our first report, we analyze more than 1,000 biotechnology transactions between 2006 and 2011 and the first three quarters of 2012. The numbers show the average upfront payment in licensing, collaboration, and development agreements was $35.5 million for all stages of development from 2006 through 2011. The numbers also show that figure moved significantly higher in 2011 and the first quarter of 2012 as the biotech market shifted toward transactions for approved products.

Posted: January 2, 2013
By: Heidrick & Struggles

Pharmaceutical R&D organizations are in the midst of a leadership crisis. Shareholders question the sustainability of the billion dollar blockbuster pharmaceutical model and large cap pharmaceutical companies question their own commitment to internal R&D. Explore how to define R&D success and hallmarks and learn how to develop the R&D leaders of tomorrow.